Amarin (FRA:EH3) Cyclically Adjusted Revenue per Share: €21.94 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:EH3 Amarin Corp PLC FRA:EH3
58 GF Score
Price €12.30
GF Value €9.97
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Amarin Cyclically Adjusted Revenue per Share?

Amarin FRA:EH3 +1.65% 58 Cyclically Adjusted Revenue per Share is €21.94 as of Jun. 2026. GuruFocus rates FRA:EH3 with a GF Score™ of 58/100 and a GF Value™ of €9.97 (Modestly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Amarin's adjusted revenue per share for the three months ended in Jun. 2026 was €1.760. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €21.94 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Amarin's average Cyclically Adjusted Revenue Growth Rate was 0.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 15.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Amarin was 21.50% per year. The lowest was -15.80% per year. And the median was 14.00% per year.

As of today (2026-08-01), Amarin's current stock price is €12.30. Amarin's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €21.94. Amarin's Cyclically Adjusted PS Ratio of today is 0.56.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Amarin was 48.00. The lowest was 0.32. And the median was 6.02.


Amarin  (FRA:EH3) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Amarin's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=12.30/21.94
=0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Amarin was 48.00. The lowest was 0.32. And the median was 6.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Amarin Cyclically Adjusted Revenue per Share Related Terms


Amarin Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Amarin's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amarin Cyclically Adjusted Revenue per Share Chart

Amarin Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.43 16.67 17.41 16.71 21.67

Amarin Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.25 21.67 21.67 21.67 21.94

FRA:EH3 vs SCLX, MIRA, NSRX: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Amarin's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amarin Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amarin's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Amarin's Cyclically Adjusted PS Ratio falls into.


FRA:EH3
58GF Score
Amarin Corp PLC FRA:EH3
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amarin Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amarin's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.76/128.3100*128.3100
=1.760

Current CPI (Jun. 2026) = 128.3100.

Amarin Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.789 100.274 3.569
201612 2.721 99.676 3.503
201703 2.398 100.374 3.065
201706 2.975 100.673 3.792
201709 2.935 100.474 3.748
201712 3.360 100.075 4.308
201803 2.498 100.573 3.187
201806 3.069 101.072 3.896
201809 3.208 101.371 4.061
201812 4.324 100.773 5.506
201903 3.946 101.670 4.980
201906 5.392 102.168 6.772
201909 5.816 102.268 7.297
201912 7.177 102.068 9.022
202003 7.768 102.367 9.737
202006 6.013 101.769 7.581
202009 6.819 101.072 8.657
202012 7.037 101.072 8.933
202103 6.052 102.367 7.586
202106 6.383 103.364 7.923
202109 6.088 104.859 7.450
202112 6.048 106.653 7.276
202203 4.320 109.245 5.074
202206 4.487 112.779 5.105
202209 4.487 113.504 5.072
202212 4.209 115.436 4.678
202303 3.954 117.609 4.314
202306 3.629 119.662 3.891
202309 3.031 120.749 3.221
202312 3.357 120.749 3.567
202403 2.536 120.990 2.689
202406 3.048 122.318 3.197
202409 1.854 121.594 1.956
202412 2.893 122.439 3.032
202503 37.588 123.405 39.082
202506 3.043 124.492 3.136
202509 2.037 124.810 2.094
202512 2.021 125.770 2.062
202603 1.863 127.830 1.870
202606 1.760 128.310 1.760

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €21.94 mean?
Amarin (FRA:EH3) has a Cyclically Adjusted Revenue per Share of €21.94 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Amarin and its competitors.
Is Amarin's Cyclically Adjusted Revenue per Share too high?
Amarin's current Cyclically Adjusted Revenue per Share is €21.94. Overall, Amarin has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amarin's Cyclically Adjusted Revenue per Share compare to SCLX and MIRA?
Amarin's Cyclically Adjusted Revenue per Share of €21.94 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Amarin and its competitors. Amarin's current Cyclically Adjusted Revenue per Share is €21.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amarin stock overvalued right now?
Based on GuruFocus' analysis, Amarin (FRA:EH3) is currently considered Modestly Overvalued. The stock's GF Value™ is €9.97, compared to a current price of €12.30 — trading 23.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €21.94. Amarin's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Amarin (FRA:EH3), the current Cyclically Adjusted Revenue per Share is €21.94 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amarin (FRA:EH3) Overvalued in 2026?

Based on GuruFocus' analysis, Amarin stock appears to be overvalued. The current stock price of €12.30 is trading 23.4% above its estimated GF Value™ of €9.97. GuruFocus considers Amarin to be Modestly Overvalued.

Key valuation signals for FRA:EH3:

  • Cyclically Adjusted Revenue per Share: €21.94
  • GF Value™: €9.97 vs. price of €12.30 (23.4% above fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the FRA:EH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amarin Business Description

Other Exchanges AMRN:USA
Address 36 Dame Street, 8th Floor, One Central Plaza, Dublin, IRL, D02 K7K5
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
58GF Score

Get the complete analysis for FRA:EH3

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.30
Price
€9.97
GF Value